Pilot Study of Cognitive Assessment in Welsh Speakers

July 23, 2014 updated by: Conor Martin

19% of Wales' population speaks Welsh. Under the Welsh Language Act 1993, every public body providing services to the public in Wales has to prepare a scheme setting out how it will provide those services in Welsh.

Diagnosing dementia requires a comprehensive assessment, an essential component of which is a cognitive assessment tool, which takes the form of a questionnaire. In clinical practice, this is currently only available through the medium of English.

The investigators objective is to measure the difference between Cognitive Assessment scores (using the Montreal cognitive assessment (MoCA)), when done in English and Welsh, in those who are cognitively impaired and whose first language is Welsh. The investigators predict that there will be a significant difference in scores in favour of the Welsh-medium tests, thus proving that the current mode of administering the test is prejudiced against patients whose first language is Welsh.

If the investigators predictions are correct, then the investigators would seek to introduce a validated Welsh-language cognitive assessment tool to the domain of the Welsh NHS.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Denbighshire
      • Bodelwyddan, Denbighshire, United Kingdom, LL18 5UJ
        • Ysbyty Glan Clwyd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Welsh Speakers - self-identify as first-language Welsh
  • Diagnosis of Dementia - recorded in patient's case notes

Exclusion Criteria:

  • Refusal
  • Intercurrent illness
  • Blind/any other disability which may prevent participant from fully completing Cognitive Assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Welsh
Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
Other: Welsh language Cognitive Assessment
This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
Active Comparator: English
Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
Other: Welsh language Cognitive Assessment
This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Difference in Cognitive Assessment Score between Welsh and English
Time Frame: at 0 and 48 hrs
at 0 and 48 hrs

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To measure the differences between participants' scores in Welsh and English and compare between different types of Dementia
Time Frame: 0 and 48hrs
We will records each participant's type of cognitive decline - e.g. Alzheimer's, Vascular, Frontal, Lewy Body, etc, and compare the differences in scores - to see whether different types of dementia will perform significantly worse or better in their first and second languages (Welsh and English).
0 and 48hrs

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Conor Martin

Collaborators

Betsi Cadwaladr University Health Board

Investigators

  • Principal Investigator: Sion Jones, MBBCh, BCUHB NHS

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Anticipated)

August 1, 2015

Study Completion (Anticipated)

October 1, 2015

Study Registration Dates

First Submitted

July 15, 2014

First Submitted That Met QC Criteria

July 23, 2014

First Posted (Estimate)

July 24, 2014

Study Record Updates

Last Update Posted (Estimate)

July 24, 2014

Last Update Submitted That Met QC Criteria

July 23, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BCUHB - PS - CAWS - 1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Impairment - e.g. Dementia

Clinical Trials on Welsh language Cognitive Assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe